Silence Therapeutics said this week that it has received a notice of allowance from the US Patent and Trademark Office on a patent application directed to a cancer target and the use of RNAi molecules against it.
The target, PKN-3, is a protein kinase C-related molecule associated with the growth of cancer cells, as well as metastasis formation, and is the target for the company's phase I siRNA-based solid tumor drug Atu-027.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
